Bausch + Lomb (BLCO) Competitors $14.06 -0.19 (-1.30%) Closing price 03:59 PM EasternExtended Trading$13.85 -0.21 (-1.46%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLCO vs. ZBH, SNN, SOLV, PEN, STVN, GKOS, IRTC, SLNO, TMDX, and INSPShould you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry. Bausch + Lomb vs. Its Competitors Zimmer Biomet Smith & Nephew SNATS Solventum Penumbra Stevanato Group Glaukos iRhythm Technologies Soleno Therapeutics TransMedics Group Inspire Medical Systems Bausch + Lomb (NYSE:BLCO) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations. Does the media refer more to BLCO or ZBH? In the previous week, Zimmer Biomet had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 8 mentions for Zimmer Biomet and 5 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 0.69 beat Bausch + Lomb's score of 0.58 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, BLCO or ZBH? Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch + Lomb$4.79B1.04-$317M-$1.03-13.65Zimmer Biomet$7.68B2.50$903.70M$4.5221.43 Do analysts recommend BLCO or ZBH? Bausch + Lomb currently has a consensus target price of $15.45, suggesting a potential upside of 9.96%. Zimmer Biomet has a consensus target price of $111.39, suggesting a potential upside of 15.01%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Bausch + Lomb.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch + Lomb 1 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.17Zimmer Biomet 2 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.35 Do insiders and institutionals have more ownership in BLCO or ZBH? 11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.8% of Bausch + Lomb shares are held by company insiders. Comparatively, 1.4% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is BLCO or ZBH more profitable? Zimmer Biomet has a net margin of 11.86% compared to Bausch + Lomb's net margin of -7.50%. Zimmer Biomet's return on equity of 12.73% beat Bausch + Lomb's return on equity.Company Net Margins Return on Equity Return on Assets Bausch + Lomb-7.50% 2.62% 1.28% Zimmer Biomet 11.86%12.73%7.34% Which has more volatility & risk, BLCO or ZBH? Bausch + Lomb has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. SummaryZimmer Biomet beats Bausch + Lomb on 16 of the 16 factors compared between the two stocks. Get Bausch + Lomb News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLCO vs. The Competition Export to ExcelMetricBausch + LombMedical Services IndustryMedical SectorNYSE ExchangeMarket Cap$4.97B$7.21B$5.67B$21.05BDividend YieldN/A2.80%4.05%3.62%P/E Ratio-13.6525.2227.9227.79Price / Sales1.0440.06397.1871.63Price / Cash7.6427.1236.1922.61Price / Book0.769.738.634.67Net Income-$317M$239.98M$3.24B$993.85M7 Day Performance-0.90%1.47%3.17%1.16%1 Month Performance16.44%5.62%10.73%4.99%1 Year Performance-13.08%17.98%35.04%12.52% Bausch + Lomb Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLCOBausch + Lomb2.1916 of 5 stars$14.06-1.3%$15.45+10.0%-16.3%$4.97B$4.79B-13.6513,500News CoverageUpcoming EarningsZBHZimmer Biomet4.9136 of 5 stars$93.79flat$110.00+17.3%-11.5%$18.56B$7.68B20.7517,000SNNSmith & Nephew SNATS2.8059 of 5 stars$30.06-0.7%$28.00-6.8%+11.6%$13.16B$5.81B13.9117,349SOLVSolventum0.9679 of 5 stars$74.08+0.4%$81.50+10.0%+31.4%$12.82B$8.25B34.3022,000Positive NewsPENPenumbra4.608 of 5 stars$238.82+0.4%$305.07+27.7%+24.2%$9.25B$1.24B225.314,500Positive NewsUpcoming EarningsSTVNStevanato Group1.5797 of 5 stars€25.55+1.3%N/A+18.1%€7.74B€1.12B50.105,521Gap UpGKOSGlaukos4.4622 of 5 stars$104.43+0.6%$134.67+29.0%-23.4%$5.97B$404.52M-44.06780Positive NewsUpcoming EarningsIRTCiRhythm Technologies1.2872 of 5 stars$138.91+2.2%$138.60-0.2%+34.4%$4.43B$591.84M-44.242,000Positive NewsUpcoming EarningsSLNOSoleno Therapeutics3.7909 of 5 stars$82.76+1.5%$108.70+31.3%+80.7%$4.17BN/A-17.9130Positive NewsTMDXTransMedics Group2.3545 of 5 stars$116.88+3.9%$127.33+8.9%-29.2%$3.95B$441.54M85.94210Positive NewsUpcoming EarningsINSPInspire Medical Systems4.9082 of 5 stars$130.17-0.1%$211.91+62.8%-5.3%$3.84B$802.80M59.981,246Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Zimmer Biomet Competitors Smith & Nephew SNATS Competitors Solventum Competitors Penumbra Competitors Stevanato Group Competitors Glaukos Competitors iRhythm Technologies Competitors Soleno Therapeutics Competitors TransMedics Group Competitors Inspire Medical Systems Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BLCO) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch + Lomb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.